Stockscreener 앱 받기
7.7577
0.26%
0.0177
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Will Enanta Pharmaceuticals Inc. continue its uptrendMarket Activity Report & Daily Profit Focused Stock Screening - Newser
Detecting price anomalies in Enanta Pharmaceuticals Inc. with AIProfit Target & Fast Gain Swing Trade Alerts - Newser
Order flow analysis tools used on Enanta Pharmaceuticals Inc.Insider Selling & Daily Market Momentum Tracking - Newser
Real time social sentiment graph for Enanta Pharmaceuticals Inc.Trade Ideas & Verified Technical Signals - Newser
Sentiment analysis tools applied to Enanta Pharmaceuticals Inc.July 2025 Catalysts & Advanced Technical Signal Analysis - Newser
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - simplywall.st
Enanta Pharmaceuticals Inc. Stock Lags Behind Sector Benchmarks2025 Market Outlook & Long-Term Investment Growth Plans - sundaytimes.kr
Published on: 2025-08-15 02:39:05 - kangso.co.kr
How high can Enanta Pharmaceuticals Inc. stock go2025 Sector Review & Daily Oversold Bounce Ideas - Newser
Visualizing Enanta Pharmaceuticals Inc. stock with heatmapsRate Hike & Fast Momentum Stock Entry Tips - Newser
Enanta Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline shifts - Investing.com
Enanta Pharmaceuticals Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingWeekly Profit Summary & Long-Term Capital Growth Strategies - Newser
Does Enanta Pharmaceuticals Inc. qualify in momentum factor screeningTrade Volume Report & Weekly Market Pulse Updates - Newser
What MACD and RSI say about Enanta Pharmaceuticals Inc.Gold Moves & Fast Entry Momentum Trade Alerts - Newser
Has Enanta Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility Review2025 Fundamental Recap & Daily Volume Surge Trade Alerts - Newser
JMP Securities Issues Positive Forecast for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price - Defense World
Enanta Pharmaceuticals shares rise 3.91% intraday after Q3 earnings beat expectations and RSVHR trial enrollment completion. - AInvest
Enanta: JMP Securities Raises PT to $25 from $24, Maintains Market Outperform Rating - AInvest
Citizens JMP raises Enanta Pharmaceuticals stock price target to $25 from $24 - Investing.com Canada
Enanta Pharmaceuticals Sees Narrower Losses And Brighter Analyst Views - Finimize
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - Stamford Advocate
Top chart patterns to watch in Enanta Pharmaceuticals Inc.Free Capital Growth With Controlled Risk Picks - Newser
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 - BioSpace
Enanta Pharmaceuticals Reports Steady Progress in Q3 2025 - TipRanks
What makes Enanta Pharmaceuticals Inc. stock price move sharplyFree Entry Plan for Oversold Reversal Stocks - Newser
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates - sharewise.com
Enanta Pharmaceuticals Q3 Earnings: $18.3M Loss, $0.85 Per Share - AInvest
Enanta Pharmaceuticals shares rise 1.85% after-hours following positive RSVHR trial progress and FDA label expansion approval. - AInvest
Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Enanta Q3 FY22 Revenue Down 17% YoY, Operations Supported by $204.1mln. - AInvest
Leading vs lagging indicators on Enanta Pharmaceuticals Inc. performanceFree Daily Profit Focused Stock Screener - Newser
Will Enanta Pharmaceuticals Inc. price bounce be sustainableRisk-Managed Swing Setup and Signal Analysis - Newser
What technical models suggest about Enanta Pharmaceuticals Inc.’s comebackProfitable Trading Blueprint with Entry Zones - Newser
Is it too late to sell Enanta Pharmaceuticals Inc.Weekly Trend Watch with Market Signals - Newser
How Interest Rate Changes Impact Enanta Pharmaceuticals Inc. Stock PerformanceSummary of Reliable Long-Term Trade Models - Newser
Enanta Pharmaceuticals Inc. recovery potential after sell offSafe Entry Screening with Data Backed Analysis - Newser
Enanta ENTA 2025Q3 Earnings Preview Downside Ahead on Weak Revenue Projections - AInvest
0.53%
2.70%
자본화:
|
볼륨(24시간):